论文部分内容阅读
目的：探讨尿激酶治疗急性下肢深静脉血栓的疗效观察。方法：回顾性分析我院2009年1月至2012年1月收治的ADVT患者80例的临床资料，对其采取了尿激酶治疗，观察临床效果。结果：本组80例，经治疗共治愈28例，有效48例，无效4例，治愈率35%，有效率95%。治疗过程中无一例有不良反应及出血迹象。其中10例溶栓过程中Fg降低(<1g/L)，暂停尿激酶溶栓，待Fg恢复正常后，继续溶栓治疗。随访6个月至3年，无复发病例。结论：经患肢远端浅静脉注射尿激酶是治疗ADVT的安全、有效的方法，在基层医院可以作为首选治疗方法。早期明确诊断，积极溶栓治疗，效果更显著。
Objective: To investigate the efficacy of urokinase in the treatment of acute lower extremity deep venous thrombosis. Methods: The clinical data of 80 patients with ADVT treated in our hospital from January 2009 to January 2012 were retrospectively analyzed. Urokinase therapy was used to observe the clinical effect. Results: The group of 80 cases, a total of 28 cases cured, effective in 48 cases, 4 cases were ineffective, the cure rate was 35%, the effective rate was 95%. No case of adverse reactions and signs of bleeding during treatment. Fg decreased (<1g / L) in 10 cases during thrombolysis, urokinase thrombolysis was suspended, until Fg returned to normal, continue thrombolytic therapy. Follow-up 6 months to 3 years, no recurrence. Conclusion: The injection of urokinase into the distal superficial vein of the limbs is a safe and effective method for the treatment of ADVT. It can be used as the preferred treatment in primary hospitals. Early diagnosis, active thrombolytic therapy, the effect is more pronounced.